<DOC>
	<DOCNO>NCT01432145</DOCNO>
	<brief_summary>This study evaluate efficacy safety 6MP combination methotrexate patient breast ovarian cancer know BRCA mutation . 6MP use instead 6TG convert cytotoxic moiety 6TG , ie . thioguanine nucleotide , reduce toxic effect . Low dose methotrexate use combination 6MP promotes formation thioguanine nucleotide .</brief_summary>
	<brief_title>A Clinical Trial Patients With BRCA Defective Tumours</brief_title>
	<detailed_description />
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>1 . Patients proven BRCA1 BRCA2 mutation appropriate exposure standard treatment , define : Breast Cancer Patients initially histologically cytologically prove locally advanced metastatic breast cancer may receive 3 previous line chemotherapy locally advanced metastatic breast cancer set . Patients must previously taxane anthracycline either adjuvant metastatic setting , provide contraindicate . Patients hormone responsive disease least 1 line hormone therapy metastatic disease . Prior treatment PARP inhibitor permissible . OR Ovarian Cancer Patients initially histologically cytologically proven ovarian cancer . Patients must disease platinum resistant platinum base therapy inappropriate . Prior treatment PARP inhibitor permissible . 2 . Patients must measurable disease computerize tomography ( CT ) MRI scan define RECIST criterion . 3 . Age ≥18 year . 4 . ECOG performance score 02 . 5 . Life expectancy &gt; 12 week . 6 . Written informed consent . 7 . Patient willing able comply protocol requirement . 8 . No prior anticancer treatment previous 4 week , palliative RT . 9 . Haematological biochemical index within range show . Lab Test Value require Haemoglobin ( Hb ) &gt; 10g/dL White Blood Count ( WBC ) &gt; 3x109/L Platelet count &gt; 100,000/μL Absolute Neutrophil count &gt; 1.5x109/L ; Serum bilirubin ≤ 2 x Upper limit normal ( ULN ) AST ( SGOT ) ALT ≤ 5 x ULN ( liver mets ) ≤ 3 x ULN ( liver mets ) Alk Phos ≤ 5 x ULN Serum creatinine ≤ 1.5 x ULN 10 . Ascites pleural effusion must drain prior therapy . 1 . Patients follow contraindication thiopurines ( 6MP 6TG ) methotrexate : family history severe liver failure ; alcoholism ; porphyria ; diffuse infiltrative pulmonary pericardial disease ; know hypersensitivity either trial agent . 2 . Patients find Low/Low genotype TPMT testing exclude . 3 . Pregnant breastfeed woman woman childbearing potential unless highly effective method contraception use ( see section 7.2.3 ) . 4 . Other active malignancy , exception adequately treat situ carcinoma cervix uteri basal squamous cell carcinoma skin . 5 . Patients know test serologically positive Hepatitis B , Hepatitis C HIV . 6 . Patients active CNS lesion exclude ( i.e. , radiographically unstable , symptomatic lesion ) . However , patient treat stereotactic therapy surgery and/or whole brain radiotherapy eligible patient remain without evidence disease progression brain ≥ 3 month prior registration date . They must also corticosteroid therapy ≥ 3 week prior registration date . 7 . Patients receive anticancer agent ( ) investigational agent within 28 day prior study drug administration . 8 . Subjects recover within one grade level ( exceed grade 2 ) baseline follow significant adverse event toxicity attribute previous anticancer treatment exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>BRCA defective</keyword>
</DOC>